NCT06001788: Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 171 | US | Ziftomenib, KO-539, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Xospata, Granulocyte colony-stimulating factor | Kura Oncology, Inc. | AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type | 08/26 | 08/27 | | |
